Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on Heartflow’s Upsized IPO

Reuters reports on the upsized U.S. initial public offering of Heartflow, a medical technology company backed by Bain Capital. The company increased the size of its offering, now targeting a valuation of up to $1.46 billion, signaling strong investor demand and adding momentum to a potential rebound for medtech IPOs after a recent downturn.

The article features commentary from IPOX® Research Associate Lukas Muehlbauer, who provides analysis on the state of the medtech sector and the specifics of Heartflow's offering. Muehlbauer notes the positive trend for the industry, stating, “The medtech sector appears to be rebounding, with Heartflow representing the industry's third sizable offering in the past month.”

He further commented on the strength of this particular IPO, highlighting its positive indicators. “While peers are trading below their conservatively priced offers, Heartflow's upsizing stands out, with the tightened price range indicating a well-covered book and strong demand following a convincing roadshow,” Muehlbauer said.

Read the full article by Arasu Kannagi Basil on Reuters: https://www.reuters.com/business/healthcare-pharmaceuticals/bain-capital-backed-heartflow-eyes-15-billion-valuation-upsized-us-ipo-2025-08-06/